|
Adult Burkitt Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells.
|
16338067 |
2007 |
|
Adult Burkitt Lymphoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
We further observed that DOK1 hypermethylation occurs frequently in a variety of primary human neoplasm including solid tumours (93% in HNC, 81% in lung cancer) and haematopoietic malignancy (64% in Burkitt's lymphoma).
|
21796618 |
2012 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We have screened the Dok1 gene for mutations from 46 individuals with B-CLL using heteroduplex analysis.
|
14730347 |
2004 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
|
Burkitt Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells.
|
16338067 |
2007 |
|
Burkitt Lymphoma
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells.
|
16338067 |
2007 |
|
Burkitt Lymphoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
We further observed that DOK1 hypermethylation occurs frequently in a variety of primary human neoplasm including solid tumours (93% in HNC, 81% in lung cancer) and haematopoietic malignancy (64% in Burkitt's lymphoma).
|
21796618 |
2012 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Thus, hypermethylation of DOK1 is a potentially critical event in human carcinogenesis, and may be a potential cancer biomarker and an attractive target for epigenetic-based therapy.
|
21796618 |
2012 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
In summary, our data show the deregulation of DOK1 gene expression by EBV and provide novel insights into the regulation of the DOK1 tumor suppressor in viral-related carcinogenesis.
|
24809689 |
2014 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Further studies are needed to more completely elucidate the functional implications of DOK1 and other members of the DOK gene family in ovarian tumorigenesis.
|
21856257 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings are suggestive for a possible tumor suppressor role of DOK1 in EOC; however its implication in enhanced EOC cell migration and proliferation restrain us to conclude that DOK1 represents a true TSG in EOC.
|
21856257 |
2011 |
|
Carotid Artery Thrombosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we found that Dok-1-/- mice exhibited significantly shortened bleeding times and accelerated carotid artery thrombosis in response to photochemical injury (p < 0.05 vs WT mice).
|
26790499 |
2016 |
|
Childhood Burkitt Lymphoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
We further observed that DOK1 hypermethylation occurs frequently in a variety of primary human neoplasm including solid tumours (93% in HNC, 81% in lung cancer) and haematopoietic malignancy (64% in Burkitt's lymphoma).
|
21796618 |
2012 |
|
Childhood Burkitt Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells.
|
16338067 |
2007 |
|
Childhood Leukemia
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Survival analyses showed that low-expressed DOK1/2 were associated with markedly shorter overall survival and leukemia free survival in both whole-cohort AML and non-M3 AML patients.
|
29150948 |
2018 |
|
Childhood Leukemia
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The data in this report show that both the DOK1 and the DOK2 adaptor proteins are constitutively expressed in the myelomonoblastic leukemia cell line, HL-60, and that expression of both proteins is induced by the chemotherapeutic differentiation causing agents, all-trans retinoic acid (atRA) and 1,25-dihydroxyvitamin D3 (VD3).
|
16823827 |
2006 |
|
Childhood Leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
To assess the so far unknown role of DOK1 in colorectal cancer (CRC), we generated DOK1 mutants which mimic the domain structure and subcellular distribution of DOK1 protein variants in leukemia patients.
|
27428427 |
2016 |
|
Childhood Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
Among the genes identified, one of particular interest was DOK1, or downstream of tyrosine kinase 1, previously recognized as a candidate tumor suppressor gene (TSG) for leukemia and other human malignancies.
|
21856257 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We have screened the Dok1 gene for mutations from 46 individuals with B-CLL using heteroduplex analysis.
|
14730347 |
2004 |
|
Chronic Lymphocytic Leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in Dok1 do not predispose to chronic lymphocytic leukemia.
|
15541476 |
2005 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, because pp60(c-src) and pp62(c-yes) appear redundant to the growth regulation of normal colonic epithelial cells, the data suggest that src-specific inhibitors might be of therapeutic value for colon cancer.
|
9056668 |
1997 |
|
Colonic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The vector was transfected into HT 29 cells, an established colon tumor cell line in which both pp60(c-src) and pp62(c-yes) are activated.
|
9056668 |
1997 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In tumors with cytoplasmic expression of DOK1, survival was improved, whereas nuclear localization of DOK1 correlated with poor outcome, indicating that compartmentalization of DOK1 is critical for CRC progression.
|
27428427 |
2016 |
|
Endometriosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In terms of the comparison between non-endometriosis and endometriosis group, the mRNA levels of AhR, Arnt, CYP1B1 and p62(dok) were essentially similar.
|
10724351 |
1999 |
|
Epithelial ovarian cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings are suggestive for a possible tumor suppressor role of DOK1 in EOC; however its implication in enhanced EOC cell migration and proliferation restrain us to conclude that DOK1 represents a true TSG in EOC.
|
21856257 |
2011 |